Since the company’s launch in 2019 in the UAE and after being recently acquired by ‘GlobalOne Healthcare Holdings LLC’ the healthcare division of Yas Holding, its mission has been to deliver science-led innovations and healthcare solutions that significantly improve patients’ lives in the UAE and beyond
Being aligned with Dubai’s Industrial Strategy 2030 that was launched in 2016 by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, of which Healthcare is a key pillar, Geltec focuses on strengthening the UAE healthcare sector and further enhancing the provision of world-class pharmaceuticals to the US, European and, GCC markets. In the first quarter of 2019, the Geltec Group launched its new production plant, manufacturing dietary supplements and pharmaceutical formulations in soft gelatin capsules and gelatin enrobed tablet forms in the UAE.
Under the leadership of ‘GlobalOne Healthcare Holdings LLC’ the healthcare arm of Yas Holdig, Geltec strategically works to create a market that is attractive for global pharmaceutical companies to manufacture and distribute their products in the UAE, aiming to achieve exponential growth in the health sector. With a total production capacity of 1.5 Billion Soft gels / Tab Gels per annum, Geltec under the leadership of Yas Holding plans to invest in further expansion to include oral solid tablets.
An environment-friendly facility
Geltec’s state-of-the-art “Green Building Certified” facility in Jafza, designed to comply with USFDA standards, has strong environmental credentials. Audited and approved by NSF GMP for OTC Monograph products and with a UL Social compliance audit successfully completed in 2019, the site currently supplies OTC Monograph products to pharmaceutical industry leaders in the USA and globally. The facility is also approved as a supplier for the products of global pharmaceutical companies. The manufacturing facility is supported by an experienced regulatory team that handles the listing and registration in various markets including the US, EU and the Middle East.
Geltec’s State-of-the-art “Green Building Certified” facility in Jafza, Designed to comply with USFDA Standards, has strong Environmental Credentials.
Embracing technology-enabled solutions
Technology and innovation have been core pillars of Geltec. The manufacturing takes place in a classified area that contains fully automatic vessels with Clean-In-Place (CIP) systems. Capsules are produced using a Hi-Tech encapsulation machine from Canada that delivers hermetically sealed high-quality capsules. A laser-guided camera system in the inspection and printing machines ensures high-quality output. The unidirectional process flow is an added advantage to the manufacturing processes.
Environmental conditions and differential pressure inside the plant is managed through automatically controlled HAVAC systems, with 99.9 per cent HEPA filters. Both the finished product and raw materials involved in the manufacturing process are tested and released in line with British and/or US pharmacopeial specifications using advanced analytical equipment meeting 21CFR regulations.
Tackling the challenges of an unstable market
Through the establishment of mutually rewarding business relationships with many leading multinational companies along with renowned global healthcare organisations, the emerging need of Geltec’s brands in particular nutraceuticals and pharmaceuticals in the EU and GCC regions, the existing monograph business in the US, and contract manufacturing business with major multinational pharmaceutical companies, Geltec has ensured its continuity of growth in the market.
The company also plans on launching oral solid dosage forms by 2022, which will lead to increase of the company’s market share in the therapeutics categories of antihypertensive, anti-diabetes, cardiovascular, anti-hypercholesterolemia and antihistamines.
Market expansion plans
With successful regulatory audits by the GCC, EU, and supply arrangements with US partners, the company aims to leverage the export strategy with further expansion into the greater Middle East and African markets.
In parallel to the continuity of the business growth, Geltec Healthcare will add more unique dosage forms to increase the range of delivery systems with the aim to cater to the growing pharmaceutical needs of the UAE and the wider region.
2019: Launched its new production plant for manufacturing supplements and formulations in soft gelatin capsules
Geltec focuses on strengthening the UAE Healthcare sector and further enchancing the provision of World-Class Pharmaceuticals to the US, European and, GCC Markets.
1.5 Billion soft gels/ tab gels produced per annum.